RESUMEN
PURPOSE: To determine if body mass index (BMI) and adipokine levels identify rheumatoid arthritis (RA) patients most likely to benefit from initiation of tumour necrosis factor inhibitors (TNFi) after methotrexate inadequate response. METHODS: This is a secondary analysis of the Rheumatoid Arthritis Comparison of Active Treatments (RACAT) trial and the (TEAR) trial. Both studies compared treatment strategies starting with conventional disease-modifying anti-rheumatic drugs (DMARDs) (triple therapy) versus etanercept plus methotrexate. We compared response rates between TNFi and triple therapy among patients with different BMI. Adipokines were measured at enrolment and associations with treatment response were examined using regression, adjusting for age, sex, BMI and baseline disease activity. RESULTS: In RACAT (n=306), participants who were normal/underweight were more likely to benefit from TNFi versus triple therapy, with greater change in Disease Activity Score in 28 and greater ACR20 response (ACR 20: 64% vs 23%, p=0.001). In contrast, overweight/obese participants had similar response to TNFi versus triple therapy (p-for-interaction=0.001). Similarly, but modest patterns were observed in TEAR (n=601; ACR20: 67% vs 52%, p=0.05). In RACAT, adipokine scores consistent with lower adiposity also predicted greater response to TNFi (ACR20: 58% vs 37%, p=0.01) with better model fit compared with BMI alone. CONCLUSIONS: Lower BMI and evidence of lower adiposity based on adipokine profiles were associated with a superior response to TNFi compared with triple therapy. There was no difference between treatments among overweight/obese participants. The results support TNFi being a particularly important therapeutic among normal/underweight patients, with implications for clinical decisions and trial design.
Asunto(s)
Antirreumáticos , Artritis Reumatoide , Humanos , Adipoquinas , Adiposidad , Antirreumáticos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Quimioterapia Combinada , Metotrexato/uso terapéutico , Obesidad , Sobrepeso/inducido químicamente , Sobrepeso/tratamiento farmacológico , Delgadez/inducido químicamente , Delgadez/tratamiento farmacológico , Resultado del Tratamiento , Inhibidores del Factor de Necrosis Tumoral/uso terapéutico , Factor de Necrosis Tumoral alfa , Ensayos Clínicos Controlados Aleatorios como AsuntoRESUMEN
Dr Claude Bennett provided local, national, and international leadership in rheumatology when it was developing as a subspecialty of internal medicine. His early contributions included work in helping to understand at the molecular level how antibodies are formed. Under his leadership, UAB grew into a nationally respected institution known for its high-quality clinical care, impactful research, and outstanding training programs. His many contributions have had a lasting effect on the fields of rheumatology, medicine, and immunology. Throughout his career, he served as a role model and was widely respected for his wise advice and superb mentorship.